¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"noise induced hearing loss"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • cell loss
    ¼¼Æ÷¼Ò½Ç
  • heat loss
    ¿­¼Õ½Ç
  • high velocity signal loss
    °í¼Ó½ÅÈ£¼Ò½Ç
  • ionization loss
    ÀÌ¿ÂÈ­¼Õ½Ç
  • insensible loss
    ºÒ°¨»ó½Ç
  • loss
    »ó½Ç, ¼Õ½Ç, ¼Ò½Ç
  • loss-of-function mutation
    ±â´É¼Ò½Çµ¹¿¬º¯ÀÌ
  • neonatal hair loss
    ½Å»ý¾ÆÅ»¸ð
  • obligatory water loss
    ÇÊ¿¬¼öºÐ¼Õ½Ç
  • organic visual loss
    ±âÁú½Ã°¢»ó½Ç
  • radiation loss
    ¹æ»ç¼±¼Õ½Ç
  • signal loss
    ½ÅÈ£¼Ò½Ç
  • vitreous loss
    À¯¸®Ã¼Å»Ãâ
  • air conduction hearing
    °ø±âÀüµµµè±â, °ø±âÀüµµÃ»·Â
  • absolute hearing
    Àý´ëÀ½°¨
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • noise
    ÀâÀ½, ¼ÒÀ½
  • noise ratio
    ÀâÀ½ºñ
  • noise standard
    ¼ÒÀ½±âÁØ
  • noise trauma
    ¼ÒÀ½¿Ü»ó
  • transportation noise
    ±³Åë¼ÒÀ½, ±³ÅëÀâÀ½
  • signal-to-noise ratio
    ½ÅÈ£´ëÀâÀ½ºñ
  • abrasion loss
    ¸¶¸ê·®, ¸¶¸ð·®
  • allowable blood loss
    Çã¿ë½ÇÇ÷·®
  • blood loss
    ½ÇÇ÷, Ç÷¾×»ó½Ç
  • cell loss
    ¼¼Æ÷¼Ò½Ç
  • heat loss
    ¿­¼Õ½Ç
  • high velocity signal loss
    °í¼Óµµ½ÅÈ£¼Ò½Ç
  • insensible loss
    ºÒ°¨»ó½Ç
  • ionization loss
    ÀÌ¿ÂÈ­¼Õ½Ç
  • loss
    ¼Õ½Ç
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • heating loss
    °¡¿­°¨·®(¡­ÊõåÖ).
  • high velocity signal loss
    °í¼Óµµ ½ÅÈ£ ¼Ò½Ç
  • insensible loss
    ºÒ°¨»ó½Ç(¡­ßÃã÷).
  • insensible water loss
    ºÒ°¨¼º(ÝÕÊïàõ) ¼öºÐ»ó½Ç(â©ÝÂßÃã÷).
  • radiation loss
    ¹æ»ç¼±¼Õ½Ç
  • Lhermittes syndrome, radiation-induced
    ¹æ»ç¼±À¸·Î À¯¹ßµÈ ·¹¹ÌÅ× ÁõÈıº
  • T1 induced dephasing
    T1 À¯µµ Å»À§»ó
  • abactio =induced abortion, abactus venter<³ª>
    ÀΰøÀ¯»ê(ìÑÍïêüß§).
  • antibiotic-induced colitis (AAC)
    Ç×»ýÁ¦À¯¹ß´ëÀå¿°, Ç×»ýÁ¦À¯¹ß¼³»ç
  • artificial hibernation =induced h.
    Àΰøµ¿¸é(¹ý)(¡­ÔÏØùÛö), ¾à¹°µ¿¸é(¹ý).
  • gradient induced phase shift effect
    °æ»ç À¯µµ À§»ó º¯À§ È¿°ú
  • hallucinogen-induced disorder
    ȯ°¢Á¦ À¯¹ß¼ºÀå¾Ö(º´)(ü³ÊÆð¥ë¯Û¡àõî¡äô)
  • heat induced hemolytic anemia
    ¿­À¯¹ß¼º ¿ëÇ÷¼º ºóÇ÷
  • induced abortion =provoked a.
    À¯¹ßÀ¯»ê(ë¯Û¡êüß§), ÀΰøÀ¯»ê(ìÑÍïêüß§) .
  • induced allergy
    À¯¹ß(¼º)¾Ë·¹¸£±â.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • speech hearing loss
    ¾îÀ½Ã»·Â¼Õ½Ç
  • speech hearing loss
    ¾îÀ½Ã»·Â¼Õ½Ç(¡­ôéæ³ áßã÷)
  • hearing amelioration =hearing improvement, hearin
    û·Â°³¼±
  • hearing distance =hearing range
    û·Â°Å¸®, °¡Ã»°Å¸®
  • acceptable noise level
    Çã¿ë¼ÒÀ½
  • acoustic noise
    À½Çâ ÀâÀ½
  • aircraft noise
    Ç×°ø(±â)¼ÒÀ½.
  • background noise
    ±âº»ÀâÀ½, ¹è°æÀâÀ½
  • background noise
    ¹è°æ ÀâÀ½
  • band noise
    ´ë¿ªÀâÀ½
  • community noise
    µµ½Ã¼ÒÀ½(ËÄËàËÛËô).
  • contrast to noise ratio
    ´ëÁ¶ ÀâÀ½ºñ
  • cosmic noise
    ¿ìÁÖÀâÀ½(ÊÙËöËô).
  • effective perceived noise level =EPNDB
    ½ÇÈ¿°¨¼ö¼ÒÀ½(Ëà̷˧ËÛËÛËô)·¹ º§.
  • factory noise
    °øÀåÀâÀ½.
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
NIPTS noise-induced permanent threshold shift
DIT deferoxamine infusion test; diet-induced thermogenesis; diiodotyrosine; drug-induced thrombocytopeni...
PIXE particle-induced x-ray emission; proton-induced x-ray emission
SIA serum inhibitory activity; stress-induced analgesia; stress-induced anesthesia; subacute infectious ...
ANT acoustic noise test; adenine nucleotide translocator; aminonitrothiazole; anterior
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
HNR Harmonics-to-Noise Ratio
IRN Iterated rippled noise
NPS Noise Power Spectrum
NEQ Noise equivalent quanta
SD/N signal-difference-to-noise ratio
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • fear of loss of love
    ½Ç¾Ö °øÆ÷
  • fluid loss
    ü¾× »ó½Ç, ü¾× ¼Õ½Ç
  • heat loss
    ¿­ ¼Õ½Ç
  • high velocity signal loss
    °í¼Óµµ ½ÅÈ£ ¼Ò½Ç
  • loss
    »ó½Ç, ¼Õ½Ç, ¼Ò¸ð
  • loss of appetite
    ½Ä¿å ºÎÁø
  • loss of consciousness
    ÀÇ½Ä »ó½Ç
  • loss of gloss
    ±¤ÅÃÀÇ ¼Ò½Ç
  • loss of molar support
    ±¸Ä¡ºÎ ÁöÁöÀÇ »ó½Ç
  • loss of structural integrity
    ±¸Á¶ÀûÀÎ ¿ÏÀü¼ºÀÇ »ó½Ç
  • patchy loss
    ¹Ý¼º »ó½Ç
  • signal loss
    ½ÅÈ£ ¼Ò½Ç
  • weight loss
    üÁß °¨¼Ò
    ´Ü½Ä, ½ÄÀÌÁ¶Àý, º´À¸·Î ÀÎÇØ ³ªÅ¸³ª¸ç, üÁö¹æÀÇ °¨¼Ò ¶Ç´Â À½½Ä¼·Ãë ºÎÁ·À¸·Î ÀÎÇÑ ¿µ¾ç°áÇÌ ½Ã¿¡ ³ªÅ¸³­´Ù.
  • bullous drug-induced exanthema
    ¾à¹°¿¡ ÀÇÇÑ ¼öÆ÷¼º ¹ßÁø
  • denture-induced hyperplasia
    ÀÇÄ¡¼º À°¾ÆÁ¾
    ?
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
alveolar bone loss The resorption of bone in the supporting structures of the maxilla or mandible as a result of periodontal disease.
(12 Dec 1998)
axon loss polyneuropathy A type of polyneuropathy in which axon degeneration is the sole/predominant feature; many aetiologies, particularly toxic and metabolic; on nerve conduction studies, affects amplitudes of the responses, but does not cause conduction slowing or block.
Synonym: axonal polyneuropathy.
(05 Mar 2000)
blood loss, surgical Loss of blood during surgery.
(12 Dec 1998)
Parallel Electron Energy Loss Spectroscopy <technique> Electron energy loss spectroscopy analyses the inelastically scattered electrons present in the beam after it has been transmitted through the sample. An electron energy loss spectrum typically consists of a monatomic decreasing background on which are superimposed a number of peaks. Each peak is characteristic of the scattering process that has occurred in the sample. The peaks can be used to obtain information about the chemical composition and electronic structure of the sample. Electron energy loss spectra are acquired typically in a magnetic sector spectrometer located under the camera chamber of the transmission electron microscope. Spatial resolution is typically limited by the minimum probe diameter of the microscope. Electron energy loss spectroscopy tends to be complimentary to EDS in that it can be used to analyse very thin samples of low Z materials.
Acronym: PEELS
(05 Aug 1998)
periodontal attachment loss Loss or destruction of periodontal tissue caused by periodontitis or other destructive periodontal diseases or by injury during instrumentation. Attachment refers to the periodontal ligament which attaches to the alveolar bone. It has been hypothesised that treatment of the underlying periodontal disease and the seeding of periodontal ligament cells enable the creating of new attachment.
(12 Dec 1998)
water loss, insensible Loss of water by diffusion through the skin and by evaporation from the respiratory tract. It is so called because we do not know that we are actually losing water at the time that it is leaving the body. (guyton, textbook of medical physiology, 8th ed, p274)
(12 Dec 1998)
weight loss Decrease in existing body weight.
(12 Dec 1998)
hair loss Hair loss may be associated with aging, hormones (androgens) or genetic predisposition. The pattern of baldness in women is different from that of men. In women there is thinning of the hair all over the scalp, but the frontal hairline is maintained. The hair loss is usually permanent. Treatment has been successful with topical minoxidil in some cases.
(13 Nov 1997)
drift cyclotron loss cone instabilities (DCLC) This is an electrostatic microinstability (frequencies at harmonics of the ion cyclotron frequency) which is of major concern in small mirror devices. Mode is driven by radial gradients in the electron density, and causes loss of ions due to non-conservation of magnetic moment (see adiabatic invariant) as they interact with the mode, and are dispersed in velocity space into the loss cone. Stabilisation is accomplished by increasing the plasma size and by partially filling the loss cone with a continuous extermal warm plasma stream.
(09 Oct 1997)
eddy-current loss <radiobiology> Energy loss due to eddy currents circulating in a resistive material.
(09 Oct 1997)
tooth loss The failure to retain teeth as a result of disease or injury.
(12 Dec 1998)
functional visual loss An apparent loss of visual acuity or visual field with no substantiating physical signs; often due to a natural concern about visual loss combined with suggestibility and a fear of the worst; best treated with reassurance.
(05 Mar 2000)
loss cone In a magnetic mirror machine, particles with a large velocity parallel to the magneitc field and a small velocity perpendicular to the field will be able to escape past the magnetic mirror (see magnetic mirror). In that case the velocity distribution function (see distribution function) will be almost zero in the region of velocity space that allows particles to escape. The shape of that region (in a velocity space diagram with parallel velocity and perpendicular velocity as the axes) is a cone. When a particle undergoes a collision, its velocity gets somewhat randomised. Particles that are scattered into that cone are lost very quickly (in one mirror bounce time). Thus it is called a loss cone. Because of the loss cone, the theoretical maximum particle confinement time of a magnetic mirror machine can be only a few times the particle collision time, this is generally seen as a showstopper for mirror-based fusion research.
(09 Oct 1997)
loss of consciousness Total unresponsiveness. An important neurologic sign.
(27 Sep 1997)
loss of heterozygosity Refers to a mutation that results in the loss of allelic uniqueness, which is often defined as a greater than or equal to 40 percent increase in signal intensity of allelic signal. Loss of heterozygosity is most frequently identified in certain chromosome regions, including 5q, 17p, and 18q.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á